Objective-Catecholamines have been shown to control bone marrow (BM)-derived cell egress, yet the cellular and molecular mechanisms involved in this effect and their subsequent participation to postischemic vessel growth are poorly understood. Methods and Results-Tyrosine hydroxylase mRNA levels, as well as dopamine (DA) and norepinephrine (NE) contents, were increased in the ischemic BM of mice with right femoral artery ligation. Angiographic score, capillary density, and arteriole number were markedly increased by treatments with DA (IP, 50 mg/kg, 5 days) or NE (IP, 2.5 mg/kg, 5 days).
M obilization and recruitment of bone marrow (BM)derived cells are of paramount importance and occupy a predominant hierarchical role in the orchestration of tissue remodeling after ischemia. Progenitor cells maintenance and mobilization in the BM are controlled by various cytokines, including colony-stimulating factors and angiogenic cytokines 1 and involve activation of proteinases, such as elastase, cathepsin G, and the matrix metalloproteinases (MMPs). Among them, MMP-9 upregulation results in the release of soluble Kit-ligand expressed by stromal cells and in the activation of BM progenitor cells motility and mobilization. 2 Furthermore, MMP-9 was demonstrated to be essential for vascular endothelial growth factor (VEGF)-induced, CXCL12induced, and placenta growth factor-induced progenitor cell mobilization. It is also known that BM-derived endothelial nitric oxide synthase (eNOS) is a substantial component of the stem cell niche and is required for the mobilization of BM-derived progenitor cells [3] [4] [5] Of interest, eNOS-deficient mice show a profoundly reduced basal activity of pro-MMP-9. As a consequence, the MMP-9 mediated release of soluble Kit-ligand from membrane KitL is reduced in eNOS-lacking mice. 3 In addition, mice deficient in eNOS show reduced vascular endothelial growth factor-induced mobilization of endothelial progenitor cells. 3 Reendothelialization and endothelial progenitor cell mobilization into the peripheral circulation after injury are also reduced in eNOS-deficient mice. 4 Finally, after ischemic challenge, eNOS knockout animals have defects in arteriogenesis and pericyte recruitment. 6 It is now well established that BM and secondary lymphoid tissues are innervated by noradrenergic sympathetic nerve fibers, which release catecholamines from the sympathetic nerve terminals. 7 Recent evidence suggests that catecholamines are also able to control BM-derived cell egress. 8 -10 Inhibition of adrenergic neurotransmission induces osteoblast suppression, bone CXCL12 downregulation, and hematopoietic stem cell mobilization. 8 Moreover, administration of a ␤2 adrenergic agonist enhances mobilization in both control and norepinephrine (NE)deficient mice. 8 Dopamine (DA) may also control BMprogenitor cell mobilization, but its role remains controversial. DA-induced activation of D2 receptor has been shown to inhibit tumor-induced mobilization of endothelial progenitor cells (EPCs) from BM to circulation, vascularization, and subsequently tumor growth. 9 In contrast, the myeloid cytokines granulocyte colony stimulating factor and granulocyte monocyte stimulating factor have been described to upregulate D5 receptor expression on immature CD34 ϩ cells and thus treatment with DA enhances BM Sca-1 ϩ c-Kit ϩ Lincell numbers. 10 During hindlimb ischemia, catecholamines have been proposed to contribute to collateral growth and angiogenesis in ischemic tissue. DA ␤-hydroxylasedeficient mice lacking cat-echolamines synthesis show an inhibition of leukocytes accumulation in the adventitia/periadventitia of collaterals and a decrease in ␣-smooth muscle actin-positive vessels. 11 In line with these results, adenoviral-mediated gene transfer of the human ␤2 adrenergic receptor to the endothelium of the rat femoral artery results in ameliorated angiographic blood flow and hindlimb perfusion after chronic ischemia, whereas angiogenesis is severely impaired in ␤2 adrenergic receptor-deficient mice subjected to femoral artery resection. 12, 13 Of interest, DA and NE are well-established activators of eNOS through cAMP/ protein kinase activation and inhibition of Rho/Rho kinaserelated pathway. 14, 15 Here, we show that catecholamines regulated BM-derived hematopoietic cells and vascular progenitor cell mobilization from BM to blood, leading to activation of their recruitment in ischemic tissue and of vessel growth in mice with hindlimb ischemia. These effects were fully blunted in lethally irradiated eNOS-deficient animals transplanted with BM from wild-type (WT) mice, highlighting a crucial role of stromal eNOS in catecholamine-induced mobilization of BM-derived progenitor cells.
Materials and Methods

Hindlimb Ischemia
Experiments were conducted according to the French veterinary guidelines and those formulated by the European Community for experimental animal use (L358-86/609EEC). WT C57BL/6 mice (nϭ10 per group) treated with or without 6-hydroxydopamine, leading to a chemical destruction of peripheral catecholaminergic fibers (6-hydroxydopamine, 250 mg/kg 1 day before ligation and 100 mg/kg 1 day after ligation, IP, Sigma), DA (50 mg/kg, 5 days, IP, Sigma), NE (2.5 mg/kg, 5 days IP, Sigma), the D1/D5 receptor agonist SKF-38393 (2.5 mg/kg, 5 days, IP, Sigma), and the ␤-adrenergic receptor agonist clenbuterol (2 mg/kg, 5 days, IP, Sigma) underwent surgical ligation of the proximal part of the right femoral artery, above the origin of the circumflexa femoris lateralis, as previously described. 16 In additional experiments, mice receiving DA and NE were also treated with or without a neutralizing antibody directed against the monocyte chemoattractant protein -1 (MCP-1) (IP, 45 g per mouse at 0, 1, 3, 5, and 7 days after the onset of ischemia).
Ten-week-old CD45.2 C57BL/6 and CD45.2 eNOS-deficient mice underwent medullar aplasia by total body irradiation (9.5 gray). BM cells were then isolated from femurs and tibias of green fluorescent protein (GFP) C57BL/6 or CD45.1 C57BL/6 WT and intravenously injected into irradiated animals. After 6 weeks, mice underwent surgical ligation of the proximal part of the right femoral artery and were treated as described above.
At the end of the treatment period, mice were anesthetized with intraperitoneal injection of pentobarbital (50 mg/kg), and microangiography was performed as previously described. 16 Paw perfusion was also assessed by laser Doppler imaging.
Immunohistochemistry
Calf muscles were frozen in liquid nitrogen-cooled isopentane. Frozen sections (7 m) were then incubated with antibodies directed against Mac-3 (1:100, BD Pharmingen) or ␣-smooth muscle cell actin (1:100, Abcam) or fluorescein isothiocyanate (FITC)-Bandeiraea simplicifolia agglutinin isolectin B4 (BSA-IB4, 1:100, Sigma) for 1 hour at room temperature. To demonstrate incorpora- tion of BM-derived cells into ischemic muscles, the gastrocnemius muscles of BM GFP chimeric mice were harvested 4 days after the onset of ischemia. Incorporated GFP-BM-derived cells were detected by immunostaining with antibody directed against GFP (1:200, Abcam) and a rhodamin-BSA-IB4 (1:100, Sigma) or with antibody directed against Mac-3 (1:100, BD Pharmingen) followed by incubation with antibody goat anti-rat Alexa Fluor 594 (1:100, Invitrogen).
Flow Cytometry Analysis
CD45.1 chimeric mice or WT animals were also used for analysis of circulatory cells infiltration. At time of euthanasia, ischemic gastrocnemius muscles were weighed, minced, and digested in 4500 U/mL collagenase I, 1250 U/mL collagenase XI, 60 U/mL DNase I, and 1000 U/mL hyaluronidase (Sigma-Aldrich) for 1 hour at 37°C. BM-derived cell, blood cell, and ischemic muscle cell suspensions were layered on Histopaque 1083 (Sigma-Aldrich) for gradient density centrifugation. All cell suspensions were labeled with FITC-conjugated anti-CD45.1 (clone A20, BD Biosciences), PerCP-conjugated anti-CD45.2 (clone 30-F11, BD Pharmingen), FITC-conjugated anti-CD11b (BD Biosciences), phycoerythrin-conjugated anti-Ly6G (clone: 1A8, BD Pharmingen), APC-conjugated anti-7/4 (ABD Serotec), APC-conjugated anti-CD34 (ABD Serotec), phycoerythrin-conjugated anti-VEGF receptor 2 (VEGFR2) (Clone: Avas12a1, eBioscience) antibody. Cells were analyzed by flow cytometry using a LSRII device (Becton Dickinson). BM-derived cells or cultured BM mononuclear cells (BMMNCs) were also labeled with rabbit anti-D3 receptor (Abcam), anti-D4 receptor (Abcam), anti-D5 receptor (Alomone Labs) and anti-␤2 receptor (Abcam) antibodies followed by incubation with phycoerythrin-conjugated anti-rabbit secondary antibody (Abcam). 
Isolation and Treatment of BMMNCs
BMMNCs were isolated by density gradient centrifugation with Histopaque 1083. BMMNCs were first plated on plastic, nonadherent cells were removed and then plated at a density of 1x10 6 cells per cm 2 on 24-well plates (Nunc) coated with 10 g/mL fibronectin (Sigma) and cultured up to 6 days in Endothelial Cell Basal Medium 2. Cells were then treated for 6 days with or without DA (10 nmol/L, Sigma), NE (1 mmol/L, Sigma), SKF-38393 (30 mmol/L, Sigma), Clenbuterol (1 mmol/L, Sigma). BMMNCs were also treated with or without N -nitro-L-arginine methyl ester (L-NAME) (nitric oxide synthase inhibitor, 10 Ϫ5 mol/L; Sigma). Endothelial cell phenotype was revealed by double-positive staining for FITC-labeled BSA-IB4 (Sigma) and DiI-labeled acetylated low-density lipoprotein (Molecular Probes) or with goat anti-eNOS antibody (Affinity Bioreagent) and subsequently goat anti-rabbit Alexa Fluor 594 antibody (Invitrogen), as previously described. 17, 18 These double-positive cells were negative for the monocytic marker CD45 (data not shown). Cell numbers were counted and expressed in cells per field. Three fields from each culture were counted.
Quantitative Reverse Transcription-Polymerase Chain Reaction
cDNA synthesis was performed with the QuantiTect Reverse Transcription Kit (Qiagen). Polymerase chain reaction was performed on StepOne Plus real time polymerase chain reaction system (Applied Biosystems) using SYBR green (Mesagreen, Eurogentec). Mouse GAPDH was used to normalize samples amplification. The following oligonucleotides served as primers:
Catecholamine Synthesis
Briefly, the animals were euthanized, their femurs and tibias were dissected, and the BM was flushed out with 5 mL of ice-cold 0.6 mol/L perchloric acid containing 1.7 mg/mL ethylene glycol tetraacetic acid and 1.1 mg/mL reduced glutathione. Samples were centrifuged for 15 minutes at 2500g at 0°C, and DA and NE were assayed into the high-performance liquid chromatography system, as previously described. 9, 19 
BMMNC Paracrine Potential
Culture medium was collected and analyzed for VEGF-A and interleukin-10 by ELISA (R&D Systems). In addition, NO production was assessed by measuring intracellular nitrosation of the NO-sensitive fluorochrome 4,5-diaminofluorescein diacetate (Alexis Biochemicals). Briefly, BMMNCs were incubated with 10 mol/L 4,5-diaminofluorescein diacetate for 3 hours (37°C). Exposure to light was avoided as far as possible throughout experimentation. Supernatants were then removed, and cells were washed in fresh 4,5-diaminofluorescein diacetate-free buffer followed by immediate fluorescence-activated cell sorting analysis. A Becton Dickinson LSRII analyzer was used to quantify fluorescence (excitation wavelength 488 nm, emission wavelength 530 nm) at the single-cell level, and data were analyzed using FACSDiva software.
Statistical Analysis
Results were expressed as meanϮSEM. Kruskal-Wallis analysis of variance was used to compare each parameter. Post hoc Mann-Whitney U tests with Bonferroni correction were then performed to identify which group differences accounted for the significant overall Kruskall-Wallis values. A value of PϽ0.05 was considered significant.
Results
Catecholamines Enhance Postischemic Revascularization
Acute treatments with DA and noradrenaline did not affect systolic blood pressure (98.5Ϯ3.1 and 100.6Ϯ3.5 mm Hg, respectively, compared with 99.4Ϯ2.8 mm Hg in PBSreceiving animals) or heart rate (508Ϯ21 and 505Ϯ23 bpm, respectively, compared with 526Ϯ19 bpm in PBS-receiving animals), 21 days after the onset of ischemia.
We then assessed the effect of catecholamines on postischemic neovascularization. DA and NE treatments increased foot perfusion, whereas sympathectomy induced by 6-hydroxydopamine administration hampered tissue perfusion recovery ( Figure 1A) . These results were confirmed by angiographic score and by capillary and arteriole density ( Figure 1B-1E ) analysis, demonstrating that catecholamines enhanced revascularization process after hindlimb ischemia. Of interest, SKF-38393, a D1/D5 dopaminergic receptor agonist, and clenbuterol, a ␤2 adrenergic receptor agonist, also highly increased foot perfusion, angiographic score, and capillary and arteriole densities, suggesting that catecholamine-related effects on postischemic revascularization resulted from D1/D5 receptor and ␤2 receptor activation.
Catecholamines Increase Mobilization and Recruitment of BM-Derived Cells
BM-derived cells have been shown to participate in tissue regeneration after ischemia. 3, 4 
Catecholamines and BM-Derived Cells With Endothelial Cell Phenotype
We first assessed the effect of catecholamines on vascular progenitor cell mobilization to blood and recruitment to ischemic tissue. Three days after ischemia, the number of CD34 ϩ /VEGFR2 ϩ cells was increased in blood of mice treated with NE, SKF-38393, and clenbuterol compared with control animals (Figure 2A ). To evaluate the recruitment of BM-derived cells in ischemic tissue, we generated chimeric mice irradiated and transplanted with BM isolated from GFP animals. We showed that DA and NE increased by 30% and 43%, respectively, the number of GFP-positive cells in ischemic tissue compared with control animals (Figure 2B , PϽ0.01; PϽ0.001). Of interest, the number of cells with endothelial phenotype, ie, positive for both GFP and BSA-IB4, was also upregulated by 236% and 188% after DA and NE treatments, respectively ( Figure 2C, PϽ0.01; PϽ0.001 ), suggesting that catecholamines may also control the ability of BM-derived cells to differentiate into cells with endothelial phenotype. To support this hypothesis, we first evaluated the cell surface expression of catecholamine receptor and then analyzed their role on the fate of cultured BM-derived cells. Flow cytometry analysis revealed that BMMNCs before and after 6 days of culture expressed ␤2, D3, D4, and D5 receptors on their surfaces and showed that DA and NE treatments did not affect catecholamine receptor levels (Figure 3A) . Differentiation of BMMNCs into cells with endothelial phenotype, revealed by double-positive staining with DiI-labeled acetylated low-density lipoprotein and BSA-IB4 or with eNOS and BSA-IB4, was increased after DA, NE, SKF-38393, and clenbuterol treatments compared with nontreated cells ( Figure 3B and 3C ). Of interest, DA and NE are well-established activators of eNOS, and eNOS has been shown to control EPC differentiation. 14, 15, 20, 21 Nitric oxide synthase inhibitor treatment (L-NAME) blunted the increase A to C, The number of CD45.1 ϩ /CD45 ϩ (total number of cells), CD45.1 ϩ /vascular endothelial growth factor receptor 2 (VEGFR2), and CD45.1 ϩ /CD34 ϩ cells was measured in the BM, the blood, and the ischemic muscle of chimeric CD45.2 WT and eNOS-deficient mice, 1 (D1) and 3 (D3) days after the onset of ischemia and treated in the number of cells with endothelial phenotype, suggesting that eNOS activation was involved in the catecholamineinduced BM-derived cell differentiation ( Figure 3B and 3C) .
Of note, cultured BMMNC proliferation was enhanced by 2-fold after DA and NE treatments ( Figure 3D, PϽ0.05) . After their recruitment to ischemic tissue, BM-derived cells are also capable of stimulating neovascularization by secretion of factors involved in tissue remodeling. To at least start to investigate this possibility, culture medium was collected from BMMNC differentiation cell cultures and assayed for VEGF and interleukin-10 contents. VEGF-A and interleukin-10 secretions were unchanged in culture medium from treated BMMNCs compared with control BMMNCs (Figure 3F and 3G) . Finally, as proangiogenic effects of BMMNCs also rely on their ability to modulate vascular function, we assessed NO release by BMMNCs. 17, 18 NO production by catecholamine-treated BMMNCs was significantly elevated compared with control BMMNCs (PϽ0.05, Figure  3E ). Concordantly, NOS inhibitor treatment (L-NAME) inhibited the catecholamine-induced NO release.
Catecholamines and BM-Derived Cells With Inflammatory Cell Phenotype
Infiltration of inflammatory cells into ischemic tissue is a hallmark of ischemia and contribute to postischemic tissue remodeling. 22 In mice treated with DA, NE, SKF-38393, and clenbuterol, the blood levels of CD45-positive cells were increased by Ϸ1.8-fold over the PBS group, 3 days after ischemia. More specifically circulating 7/4 hi and 7/4 low monocytes number was increased by Ϸ2and 2.4-fold, respectively, in mice treated with catecholamines compared with controls ( Figure 4A, PϽ0.05) . In the ischemic tissue, the number of CD45-positive cells raised between day 1 and day 3 and returned to basal levels at day 21 ( Figure 4B ). In particular, 7/4 hi and 7/4 low monocyte count peaked at day 3 following ischemia ( Figure 4B ). Interestingly, DA and NE increased this time-dependent monocyte infiltration ( Figure  4B) . Similarly, the number of macrophages rapidly increased after the onset of ischemia and completely faded between day 7 and day 14 ( Figure 5A ). Of note, macrophage number within the ischemic tissue was still enhanced by 82%, 110%, 80% and 70% after treatment with DA, NE, SKF-38393, and clenbuterol, respectively, 21 days after femoral artery ligation ( Figure 5B ). To determine whether infiltrated macrophages originate from BM, double-positive staining with GFP and Mac-3 was performed on muscle of BM GFP chimeric mice. The number of GFP and Mac-3-positive cells were upregulated by catecholamine administration (Figure 5C, PϽ0.01) .
Finally, to specifically unravel the role of BM-derived inflammatory cells in the catecholamine-related effects, we performed additional experiments using neutralizing antibody directed against the chemokine MCP-1. MCP-1 and its receptor CCR2 have been shown to play a key role in postischemic BM-derived inflammatory cell mobilization and infiltration in ischemic tissues. 23 We showed that inhibition of MCP-1 signaling fully abrogated the catecholamine-related effects on postischemic vessel growth and macrophage number ( Figure 5D ).
Altogether, our results suggest that catecholamines control BM-derived cell mobilization and subsequently tissue regeneration.
Catecholamines Control BM-Derived Cell Egress Through Upregulation of Stromal eNOS
Quantitative polymerase chain reaction analysis of BM samples showed that tyrosine hydroxylase mRNA levels, the enzyme catalyzing the conversion of tyrosine into L-DOPA, the precursor of both DA and NE, were upregulated 24 hours after the onset ischemia and returned to basal levels thereafter ( Figure 6A ). Of interest, the regulation of tyrosine hydroxylase levels was associated with a raise in DA and NE contents, suggesting that ischemia activated the BM sympathetic nervous system ( Figure 6B ). BM-derived cells had variable expression of cell surface catecholamine receptors, depending on the time course after the onset of ischemia. Receptors levels were decreased 12 hours after ischemia and returned to basal levels 24 hours after ischemia. However, catecholamine receptor contents decreased again 48 and 72 hours after femoral artery ligation ( Figure 6C ).
Of interest, as for catecholamine synthesis, in the ischemic leg, BM eNOS mRNA levels were also increased by 280% at 24 hours after the onset of ischemia compared with control animals. It is noteworthy that eNOS mRNA contents were unchanged in the BM of nonischemic leg ( Figure 6D ). In addition, exogenous catecholamine treatment enhanced eNOS expression in the BM of ischemic leg, only ( Figure  6E ).
Overall, these results suggested that catecholamines may control eNOS expression in the BM and prompted us to investigate the role of eNOS regulation in catecholamineinduced mobilization and recruitment of BM-derived cells. To this end, we generated chimeric CD45.2 eNOS Ϫ/Ϫ or WT mice lethally irradiated and retransplanted with BM derived cells from CD45.1 WT mice. In the absence of ischemia, the number of CD45.1 ϩ CD45.2 ϩ cells was similar in eNOS Ϫ/Ϫ and WT chimeric animals (data not shown). In the BM, the number of CD45.1 ϩ CD45 ϩ and CD45.1 ϩ CD34 ϩ cells was decreased by 1.3-and 3.3-fold, respectively, in WT chimeric mice compared with eNOS Ϫ/Ϫ chimeric mice 3 days after ischemia, suggesting that eNOS deficiency reduced BMderived cell mobilization from BM to blood ( Figure 7A-7C ). In addition, catecholamine administration reduced the number of BM cells positive for CD45.1 and VEGFR2 in WT chimeric mice but not in eNOS-deficient chimeric animals ( Figure 7B ). In the blood, 1 and 3 days after ischemia, the number of CD45.1 ϩ CD45 ϩ cells or CD45.1 ϩ VEGFR2 ϩ cells or CD45.1 ϩ CD34 ϩ cells were higher in chimeric WT mice compared with eNOS Ϫ/Ϫ chimeric animals, and catecholamine treatments were not able to rescue the defective phenotype in eNOS-deficient animals (Figure 7) . Similarly, in the ischemic muscle, the number of CD45.1 ϩ CD45 ϩ , CD45.1 ϩ VEGFR2 ϩ , or CD45.1 ϩ CD34 ϩ cells was higher in chimeric WT compared with eNOS Ϫ/Ϫ chimeric animals, and catecholamine treatments did not restore the recruitment of circulating cells in the ischemic area of eNOS Ϫ/Ϫ animals (Figure 7 ). Together, these results showed that the lack of eNOS in the BM inhibited the mobilization and recruitment of BM-derived cells and suggested that eNOS controlled the catecholamine-related effect on mobilization and recruitment of BM cells. In line with these results, catecholamines were unable to stimulate postischemic inflammation and vessel growth in eNOS-deficient chimeric animals (Figure 8 ).
Discussion
In the present study, we showed that catecholamines modulate postischemic revascularization through stromal eNOS activation and regulation of BM-derived cell egress. Similarly, hematopoietic stem cell mobilization is severely altered in NE-deficient mice or after ␤-adrenergic antagonist administration, highlighting a key role of the sympathetic nervous system in this setting. 8 In sharp contrast, BM DA has been reported to inhibit the mobilization of BM-derived EPCs during malignant tumor growth through activation of D2 receptors. 9 In our study, treatments with DA or with the D1/D5 receptor agonist SKF-38393 trigger BM-derived cell egress and postischemic vessel growth. In line with our results, D3/D5 receptor activation has been shown to enhance proliferation and motility of human CD34 ϩ progenitor cells, repopulation of mouse BM, and egress of progenitor cells to circulation. 10 It is noteworthy that D2 receptor blockade using eticlopride also stimulates BM-derived cell mobilization and triggers circulatory cells infiltration, as well as postischemic vessel growth (data not shown). Our study has broadened the understanding of the function of sympathetic nervous system in the regulation of the retention, proliferation, and recruitment of hematopoietic progenitor cells, demonstrating that ␤2 adrenergic and D1/D5 receptor activate progenitor mobilization, whereas D2 receptor inhibits it.
Our results also demonstrate that there is a significant increase in tyrosine hydroxylase mRNA levels, which in turn is correlated with upregulation in the concentration of BM DA and NE, suggesting that limb ischemia triggers catecholamines synthesis within the BM. However, both nerve cells and other cells may release catecholamines in the BM. 24, 25 Of interest, whatever the type of catecholamine-producing cells, these effects were observed in the BM of ischemic legs only. In addition, we have also shown that DA and NE treatments enhance BM eNOS mRNA levels and that eNOS-related pathways are required for catecholamine-induced progenitor cell mobilization from BM. In previous studies, eNOS has been identified as a specific mediator of progenitor cell mobilization from the BM to circulation. 3 Similarly, in eNOS-null mice, the effect of estradiol on mobilization of EPCs was lost, as was the functional improvement in recovery from acute myocardial ischemia. 4 Nevertheless, it is also likely that DA and NE can activate BM progenitor cell mobilization through alternative pathways, including Wnt signaling and upregulation of ␤-catenin abundance. 10 We also unravel important function for neurotransmitters in regulating 2 additional key processes of postischemic revascularization: recruitment to ischemic tissues and differentiation. When stimulated by neurotransmitters of the adrenergic system, the number of BM-derived cells recruited to ischemic area was markedly increased. Likewise, NE and DA has been shown to increase the motility and the migration potential of immature CD34 ϩ cells through activation of MT1-MMP or MMP2. 10 Finally, our data have demonstrated an important and direct function for the nervous system in regulating the differentiation of BM cells to cells with endothelial phenotype. Cultured BMMNCs expressed receptor for DA and NE and catecholamine-induced NO release controls BM cell differentiation. Of interest, DA and NE are well-established activators of eNOS, and eNOS has been shown to control EPC differentiation. 14, 15, 20, 21 In diabetes, EPCs were shown trapped within the diabetic BM as a result of a lack of inherent sympathetic denervation that can alter circadian release of EPCs from the BM capacity. 24 Our novel findings would indicate that catecholamines or ␤2 and D1/D5 agonists could be interesting treatments to restore physiological EPC egress from the BM and improved vascular repair in pathological tissues. Whereas our work unravels the role of catecholamines on BM-derived cell mobilization, we cannot rule out the implication of other mechanisms. Hence, it has been previously demonstrated that in vivo adenoviral-mediated gene transfer of the human ␤2 adrenergic receptor to the endothelium of the rat femoral artery improves angiographic score, hindlimb perfusion, and capillary density. 12 In addition, stimulation of endogenous and overexpressed ␤2 adrenergic receptor on endothelial cells in vitro was found to regulate cell number by inducing proliferation and [ 3 H]thymidine incorporation through means of extracellular receptor-activated kinase and vascular endothelial growth factor or activation of nuclear factor-B. 12, 13 In summary, we show here that the sympathetic nervous system regulates, through eNOS signaling, the egress of BM-derived vascular progenitor cells and BM-derived inflammatory cells, leading to activation of postischemic vessel growth. Our study also suggests that regulation of sympathetic nervous system activation may constitute an innovative strategy to modulate BM-derived cell mobilization and vessel growth in cancer or cardiovascular ischemic diseases. 
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